Taken together, these data point to an adverse effect of an activated NEU1/β-GAL/PPCA complex on the heart after I/R and suggest that targeting this complex may lead to a novel therapeutic strategy to reduce adverse remodelling and heart failure after MI. This evidence concerns the gene NEU1 and myocardial infarction.